Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 13/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
| ▸ | PYGM | P11217 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15964553 | 0.82 | AADAT (0.50) | SRD5A1RIPK1DRD2DRD4NOTUM | |
| SCHEMBL19224678 | 0.79 | ROCK1 (0.39) | — | |
| SCHEMBL18744969 | 0.78 | DRD4 (0.47) | SRD5A1RIPK1DRD2DRD4PYGL | |
| SCHEMBL19224489 | 0.75 | RIPK1 (0.42) | RIPK1DRD2DRD4PYGL | |
| SCHEMBL21220936 | 0.75 | RIPK1 (0.42) | SRD5A1RIPK1DRD2DRD4 | |
| SCHEMBL11255201 | 0.74 | SRD5A1 (0.59) | SRD5A1NOTUMSRD5A2 | |
| SCHEMBL31656024 | 0.73 | SRD5A1 (0.40) | SRD5A1RIPK1 | |
| SCHEMBL11863402 | 0.72 | DRD4 (0.46) | SRD5A1DRD2DRD4NOTUMAADAT | |
| SCHEMBL21221071 | 0.72 | RIPK1 (0.42) | RIPK1 | |
| Hydrochloric Acid SCHEMBL11858272 | 0.71 | DRD4 (0.45) | SRD5A1DRD2DRD4NOTUMAADAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342771-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2018-07-04 | — | — | EP | disclosed |